Considering the complicated mechanisms of immune escape of cancers, targeting different stages of the cancer immunity cycle using combinatorial approaches (e.g., using drugs that will alter immunosuppressive tumor microenvironment along with neoantigen vaccine or boosting neoantigen presentation using immunomodulators like GM-CSF, anti-CD-40 etc.)may be more effective. This evidence concerns the gene CSF2 and cancer.